National Cancer Institute. Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version. https://www​.cancer.gov​/types/ovarian/hp/ovarian-epithelial-treatment-pdq. Accessed November 17, 2016. [PMC free article: PMC66007] [PubMed: 26389443]

Institute of Medicine, Committee on the State of the Science in Ovarian Cancer Research, Board on Health Care Services, et al. Ovarian Cancers: Evolving Paradigms in Research and Care. Washington (DC): National Academies Press (US); 2016. PMID: 27253000. [PubMed: 27253000]

Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1-5. PMID: 24219974. http://dx.doi.org/10​.1016/j.ijgo.2013.10.001 [PubMed: 24219974]

National Cancer Institute. Staging. https://www​.cancer.gov​/about-cancer/diagnosis-staging​/staging. Accessed November 2, 2016.

Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet. 2014;384(9951):1376-88. PMID: 24767708. http://dx.doi.org/10​.1016/S0140-6736(13)62146-7 [PubMed: 24767708]

Kurman RJ, Shih Ie M. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016;186(4):733-47. PMID: 27012190. http://dx.doi.org/s10​.1016/j.ajpath.2015.11.011 [PMC free article: PMC5808151] [PubMed: 27012190]

McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420-32. http://dx.doi.org/10​.1097/PAT.0b013e328348a6e7 [PubMed: 21716157]

Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2013. http://seer​.cancer.gov/csr/1975_2013/. Accessed November 6, 2016.

American Cancer Society. Cancer Facts & Figures 2017. Atlanta: American Cancer Society. 2017.

U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2014 Incidence and Mortality Web-based Report. www​.cdc.gov/uscs. Accessed June 28, 2017.

National Cancer Institute. Cancer Stat Facts: Ovarian Cancer. https://seer​.cancer.gov​/statfacts/html/ovary.html. Accessed June 28, 2017.

Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014. https://seer​.cancer.gov/csr/1975_2014/. Accessed June 28, 2017.

National Cancer Institute. NCI Dictionary of Cancer Terms. https://www​.cancer.gov​/publications/dictionaries​/cancer-terms. Accessed November 2, 2016.

Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int 2014;934261. PMID: 24868556. http://dx.doi.org/10​.1155/2014/934261 [PMC free article: PMC4017729] [PubMed: 24868556]

Reade CJ, McVey RM, Tone AA, et al. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can. 2014;36(2):133-40. PMID: 24518912. http://dx.doi.org/10​.1016/S1701-2163(15)30659-9 [PubMed: 24518912]

Kurman RJ, Shih Ie M Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42(7):918-31. PMID: 21683865. http://dx.doi.org/10​.1016/j.humpath.2011.03.003 [PMC free article: PMC3148026] [PubMed: 21683865]

North American Association of Central Cancer Registries. Average-annual age-adjusted cancer incidence rates by race/ethnicity, sex, and registry for selected sites. http://www​.naaccr.org​/DataandPublications/CINAPubs.aspx. Accessed November 2, 2016.

Permuth-Wey J, Besharat A, Sellers T Epidemiology of ovarian cancer: An update. In: Advances in diagnosis and management of ovarian cancer. Farghaly SA, editor. New York: Springer Science and Business Media; 2014. PMID: None.

Wentzensen N, Poole EM, Trabert B, et al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016;34(24):2888-98. PMID: 27325851. http://dx.doi.org/10​.1200/JCO.2016.66.8178 [PMC free article: PMC5012665] [PubMed: 27325851]

Shulman LP, Dungan JS Cancer genetics: risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer. Cancer Treat Res. 2010;156:69-85. PMID: 20811826. http://dx.doi.org/10​.1007/978-1-4419-6518-9_6 [PMC free article: PMC3086477] [PubMed: 20811826]

Lu KH, Daniels M Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer. 2013;12(2):273-7. PMID: 23765559. http://dx.doi.org/10​.1007/s10689-013-9664-5 [PMC free article: PMC3820416] [PubMed: 23765559]

Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011;12(1):49-55. PMID: 21145788. http://dx.doi.org/10​.1016/S1470-2045(10)70265-5 [PMC free article: PMC3670774] [PubMed: 21145788]

Hendriks YM, de Jong AE, Morreau H, et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin. 2006;56(4):213-25. PMID: 16870997. http://dx.doi.org/10​.3322/canjclin.56.4.213 [PubMed: 16870997]

Hampel H, Bennett RL, Buchanan A, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70-87. PMID: 25394175. http://dx.doi.org/10​.1038/gim.2014.147 [PubMed: 25394175]

Song H, Ramus SJ, Tyrer J, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 2009;41(9):996-1000. PMID: 19648919. http://dx.doi.org/10​.1038/ng.424 [PMC free article: PMC2844110] [PubMed: 19648919]

Pharoah PD, Tsai YY, Ramus SJ, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013;45(4):362-70, 70e1-2. PMID: 23535730. http://dx.doi.org/10​.1038/ng.2564 [PMC free article: PMC3693183] [PubMed: 23535730]

Permuth-Wey J, Lawrenson K, Shen HC, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun. 2013;4:1627. PMID: 23535648. http://dx.doi.org/10​.1038/ncomms2613 [PMC free article: PMC3709460] [PubMed: 23535648]

Kuchenbaecker KB, Ramus SJ, Tyrer J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015;47(2):164-71. PMID: 25581431. http://dx.doi.org/10​.1038/ng.3185 [PMC free article: PMC4445140] [PubMed: 25581431]

Bolton KL, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010;42(10):880-4. PMID: 20852633. http://dx.doi.org/10​.1038/ng.666 [PMC free article: PMC3125495] [PubMed: 20852633]

Bojesen SE, Pooley KA, Johnatty SE, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013;45(4):371-84, 84e1-2. PMID: 23535731. http://dx.doi.org/10​.1038/ng.2566 [PMC free article: PMC3670748] [PubMed: 23535731]

National Institute for Health and Care Excellence (NICE). Clinical guideline [CG164]: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. 2013. PMID: None.

Daly MB, Pilarski R, Axilbund JE, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016;14(2):153-62. PMID: 26850485. http://dx.doi.org/10​.6004/jnccn.2016.0018 [PubMed: 26850485]

Moyer VA, Force USPST. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(4):271-81. PMID: 24366376. http://dx.doi.org/10​.7326/M13-2747 [PubMed: 24366376]

Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303-14. PMID: 18294997. http://dx.doi.org/10​.1016/S0140-6736(08)60167-1 [PubMed: 18294997]

Whittemore AS, Harris R, Itnyre J Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136(10):1184-203. PMID: 1476141. [PubMed: 1476141]

Fortner RT, Ose J, Merritt MA, et al. Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort. Int J Cancer. 2015;137(5):1196-208. PMID: 25656413. http://dx.doi.org/10​.1002/ijc.29471 [PMC free article: PMC6284794] [PubMed: 25656413]

Gates MA, Rosner BA, Hecht JL, et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171(1):45-53. PMID: 19910378. http://dx.doi.org/10​.1093/aje/kwp314 [PMC free article: PMC2796984] [PubMed: 19910378]

Merritt MA, De Pari M, Vitonis AF, et al. Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod. 2013;28(5):1406-17. PMID: 23315066. http://dx.doi.org/10​.1093/humrep/des466 [PMC free article: PMC3627336] [PubMed: 23315066]

Yang HP, Trabert B, Murphy MA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer. 2012;131(4):938-48. PMID: 21960414. http://dx.doi.org/10​.1002/ijc.26469 [PMC free article: PMC3505848] [PubMed: 21960414]

Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607-18. PMID: 23733771. http://dx.doi.org/10​.1200/JCO.2012.48.2596 [PMC free article: PMC3699726] [PubMed: 23733771]

Hartge P, Whittemore AS, Itnyre J, et al. Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. Obstet Gynecol. 1994;84(5):760-4. PMID: 7936508. [PubMed: 7936508]

Rosner BA, Colditz GA, Webb PM, et al. Mathematical models of ovarian cancer incidence. Epidemiology. 2005;16(4):508-15. PMID: 15951669. [PubMed: 15951669]

Pfeiffer RM, Park Y, Kreimer AR, et al. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med. 2013;10(7):e1001492. PMID: 23935463. http://dx.doi.org/10​.1371/journal.pmed.1001492 [PMC free article: PMC3728034] [PubMed: 23935463]

Li K, Husing A, Fortner RT, et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. Br J Cancer. 2015;112(7):1257-65. PMID: 25742479. http://dx.doi.org/10​.1038/bjc.2015.22 [PMC free article: PMC4385951] [PubMed: 25742479]

Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-75. PMID: 20810374. http://dx.doi.org/10​.1001/jama.2010.1237 [PMC free article: PMC2948529] [PubMed: 20810374]

Jacoby VL, Grady D, Wactawski-Wende J, et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med. 2011;171(8):760-8. PMID: 21518944. http://dx.doi.org/10​.1001/archinternmed.2011.121 [PubMed: 21518944]

Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009;113(5):1027-37. PMID: 19384117. http://dx.doi.org/10​.1097/AOG.0b013e3181a11c64 [PMC free article: PMC3791619] [PubMed: 19384117]

Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547-53. PMID: 24567435. http://dx.doi.org/10​.1200/JCO.2013.53.2820 [PMC free article: PMC4026578] [PubMed: 24567435]

Falconer H, Yin L, Gronberg H, et al. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015;107(2). PMID: 25628372 http://dx.doi.org/10​.1093/jnci/dju410 [PubMed: 25628372]

Guldberg R, Wehberg S, Skovlund CW, et al. Salpingectomy as standard at hysterectomy? A Danish cohort study, 1977-2010. BMJ Open. 2013;3(6). PMID: 23794553 http://dx.doi.org/10​.1136/bmjopen-2013-002845 [PMC free article: PMC3686168] [PubMed: 23794553]

Ammerican College on Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice. Committee opinion no. 620: Salpingectomy for ovarian cancer prevention. Obstet Gynecol. 2015;125(1):279-81. PMID: 25560145. http://dx.doi.org/10​.1097/01.AOG.0000459871.88564.09 [PubMed: 25560145]

Society of Gynecologic Oncology (SGO). SGO clinical practice statement: Salpingectomy for ovarian cancer prevention. https://www​.sgo.org/clinical-practice​/guidelines​/sgo-clinical-practice-statement-salpingectomy-for-ovarian-cancer-prevention. Accessed November 23, 2016.

Rice MS, Murphy MA, Tworoger SS Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis. J Ovarian Res. 2012;5(1):13. PMID: 22587442. http://dx.doi.org/10​.1186/1757-2215-5-13 [PMC free article: PMC3386864] [PubMed: 22587442]

Walker JL, Powell CB, Chen LM, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121(13):2108-20. PMID: 25820366. http://dx.doi.org/10​.1002/cncr.29321 [PubMed: 25820366]

Havrilesky LJ, Gierisch JM, Moorman PG, et al. Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer. Evidence Report/Technology Assessment No. 212. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.). AHRQ Publication No 13-E002-EF PMID: None.

Bristow RE, Chang J, Ziogas A, et al. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol. 2013;121(6):1226-34. PMID: 23812456. http://dx.doi.org/10​.1097/AOG.0b013e3182922a17 [PubMed: 23812456]

Bristow RE, Chang J, Ziogas A, et al. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol. 2014;132(2):403-10. PMID: 24361578. http://dx.doi.org/10​.1016/j.ygyno.2013.12.017 [PubMed: 24361578]

Chan JK, Kapp DS, Shin JY, et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol. 2007;109(6):1342-50. PMID: 17540806. http://dx.doi.org/10​.1097/01.AOG.0000265207.27755.28 [PubMed: 17540806]

Goff BA, Mandel LS, Melancon CH, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291(22):2705-12. PMID: 15187051. http://dx.doi.org/10​.1001/jama.291.22.2705 [PubMed: 15187051]

Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221-7. PMID: 17154394. http://dx.doi.org/10​.1002/cncr.22371 [PubMed: 17154394]

Ebell MH, Culp MB, Radke TJ A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer. Am J Prev Med. 2016;50(3):384-94. PMID: 26541098. http://dx.doi.org/10​.1016/j.amepre.2015.09.023 [PubMed: 26541098]

Bast RC, Jr., Skates S, Lokshin A, et al. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. International Journal of Gynecological Cancer. 2012;22 Suppl 1:S5-8. http://dx.doi.org/10​.1097/IGC.0b013e318251c97d [PMC free article: PMC3389992] [PubMed: 22543921]

Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. British journal of obstetrics and gynaecology. 1990;97(10):922-9. PMID: 2223684. [PubMed: 2223684]

Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40-6. http://dx.doi.org/10​.1016/j.ygyno.2008.08.031 [PMC free article: PMC3594094] [PubMed: 18851871]

Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(10 Suppl):2004-10. PMID: 8634992. [PubMed: 8634992]

Manegold-Brauer G, Bellin AK, Tercanli S, et al. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging. Arch Gynecol Obstet. 2014;289(3):491-8. PMID: 24253338. http://dx.doi.org/10​.1007/s00404-013-3081-8 [PubMed: 24253338]

Woolas RP, Xu FJ, Jacobs IJ, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993;85(21):1748-51. PMID: 8411259. [PubMed: 8411259]

Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327-40. PMID: 19282241. http://dx.doi.org/10​.1016/S1470-2045(09)70026-9 [PubMed: 19282241]

Stormo AR, Cooper CP, Hawkins NA, et al. Physician characteristics and beliefs associated with use of pelvic examinations in asymptomatic women. Prev Med. 2012;54(6):415-21. PMID: 22484240. http://dx.doi.org/10​.1016/j.ypmed.2012.03.012 [PubMed: 22484240]

Doroudi M, Kramer B, Pinsky P The bimanual ovarian palpation examination in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications. J Med Screen. 2016;0(0):1-3. PMID: 27903809. http://dx.doi.org/10​.1177/0969141316680381 [PubMed: 27903809]

Qaseem A, Humphrey LL, Harris R, et al. Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(1):67-72. PMID: 24979451. http://dx.doi.org/10​.7326/M14-0701 [PubMed: 24979451]

US Preventive Services Task Force. Screening for Gynecologic Conditions With Pelvic Examination: US Preventive Services Task Force Recommendation Statement. JAMA. 2017;317(9):947-53. PMID: None. http://dx.doi.org/10​.1001/jama.2017.0807 [PubMed: 28267862]

American College of Obstetricians and Gynecologists (ACOG). The role of the obstetrician–gynecologist in the early detection of epithelial ovarian cancer. Committee Opinion No. 477. Obstet Gynecol. 2011;117:742-6. PMID: 21343791. http://dx.doi.org/10​.1097/AOG.0b013e31821477db [PubMed: 21343791]

Moyer VA, U. S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.[Summary for patients in Ann Intern Med. 2012 Dec 18;157(12):I-56; PMID: 23362519]. Ann Intern Med. 2012;157(12):900-4. PMID: 22964825. http://dx.doi.org/10​.7326/0003-4819-157-11-201212040-00539 [PubMed: 22964825]

American Academy of Family Physicians. Clinical Preventive Service Recommendation: Ovarian Cancer. http://www​.aafp.org/patient-care​/clinical-recommendations​/all/ovarian-cancer​.html. Accessed November 17, 2016.

Smith RA, Brooks D, Cokkinides V, et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63(2):88-105. PMID: 23378235. http://dx.doi.org/10​.3322/caac.21174 [PubMed: 23378235]

Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2016;66(2):96-114. http://dx.doi.org/10​.3322/caac.21336 [PubMed: 26797525]

Pandharipande PV, Harvey HB, Javitt MC, et al. ACR Appropriateness Criteria® ovarian cancer screening. 2012. PMID: None.

Baldwin LM, Trivers KF, Matthews B, et al. Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations?.[Erratum appears in Ann Intern Med. 2012 Jun 19;156(12):908]. Ann Intern Med. 2012;156(3):182-94. PMID: 22312138. http://dx.doi.org/10​.7326/0003-4819-156-3-201202070-00006 [PubMed: 22312138]

Baldwin LM, Trivers KF, Andrilla CH, et al. Accuracy of ovarian and colon cancer risk assessments by U.S. physicians. J Gen Intern Med. 2014;29(5):741-9. PMID: 24519100. http://dx.doi.org/10​.1007/s11606-014-2768-2 [PMC free article: PMC4000350] [PubMed: 24519100]

U.S. Food and Drug Administration. The FDA recommends against using screening tests for ovarian cancer screening: FDA Safety Communication. http://www​.fda.gov/MedicalDevices​/Safety​/AlertsandNotices/ucm519413.htm. Accessed December 30, 2016.

Abcodia. Abcodia Statement on the ROCA Test for Ovarian Cancer Screening. https://www​.rocatest​.com/about-us/news-events​/news-item/abcodia-statement-roca-test-ovarian-cancer-screening/. Accessed December 30, 2016.

Danforth KN, Im TM, Whitlock EP Addendum to Screening for Ovarian Cancer: Evidence Update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. AHRQ Publication No 12-05165-EF4 Rockville, MD: Agency for Healthcare Research and Quality: . April 2012. PMID: None.

Barton M, Lin K Screening for Ovarian Cancer: Evidence Update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. AHRQ publication no. 12-05165-EF3. Rockville, MD: Agency for Healthcare Research and Quality: . April 2012. PMID: None.

Nelson H, Westhoff C, Piepert J, et al. Screening for Ovarian Cancer: Brief Evidence Update. AHRQ Publication No 04-0542-B. Rockville, MD: Agency for Healthcare Research and Quality: May 2004. PMID: None.

Kaiser Permanente Southern California. Ovarian Cancer Screening Clinical Practice Guideline. Recommendations and Rationale. December 2014. PMID: None.

Reade CJ, Riva JJ, Busse JW, et al. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2013;130(3):674-81. http://dx.doi.org/10​.1016/j.ygyno.2013.06.029 [PubMed: 23822892]

Wallace BC, Small K, Brodley CE, et al., editors. Deploying an interactive machine learning system in an evidence-based practice center: abstrackr. 2nd ACM SIGHIT International Health Informatics Symposium 2012. PMID: None.

Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21-35. PMID: 11306229. http://dx.doi.org/10​.1016/S0749-3797(01)00261-6 [PubMed: 11306229]

Daya D, Cheung A, Khunamornpong S, et al. Tumors of the peritoneum: epithelial tumors of Müllerian type. in: RJ Kurman, ML Carcangiu, CS Herrington, RH Young (Eds.) In: WHO classification of tumors of female reproductive organs. 4th edn: International Agency for Research on Cancer, Lyon; 2014. p. 92-3. PMID: None.

Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295-303. PMID: 21642681. http://dx.doi.org/10​.1001/jama.2011.766 [PubMed: 21642681]

Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945-56. PMID: 26707054. http://dx.doi.org/10​.1016/s0140-6736(15)01224-6 [PMC free article: PMC4779792] [PubMed: 26707054]

Menon U, Kalsi JK, Gentry-Maharaj A, et al. Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. J Clin Oncol. 2016;34(2):201-2. PMID: 26573079. http://dx.doi.org/10​.1200/JCO.2015.64.1365 [PubMed: 26573079]

Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726-32. PMID: 20335313. http://dx.doi.org/10​.7326/0003-4819-152-11-201006010-00232 [PubMed: 20335313]

Berkman ND, Santaguida PL, Viswanathan M, et al. In: The Empirical Evidence of Bias in Trials Measuring Treatment Differences. Rockville (MD)2014. PMID: 25392898. [PubMed: 25392898]

Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. PMID: 15205295. http://dx.doi.org/10​.1136/bmj.328.7454.1490 [PMC free article: PMC428525] [PubMed: 15205295]

Andersen MR, Drescher CW, Zheng Y, et al. Changes in cancer worry associated with participation in ovarian cancer screening. Psychooncology. 2007;16(9):814-20. PMID: 17225260. http://dx.doi.org/10​.1002/pon.1151 [PubMed: 17225260]

Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353(9160):1207-10. PMID: 10217079. http://dx.doi.org/10​.1016/s0140-6736(98)10261-1 [PubMed: 10217079]

Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993;306(6884):1030-4. PMID: 8490497. http://dx.doi.org/10​.1136/bmj.306.6884.1030 [PMC free article: PMC1677033] [PubMed: 8490497]

Gren L, Broski K, Childs J, et al. Recruitment methods employed in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Clin. 2009;6(1):52-9. PMID: 19254935. http://dx.doi.org/10​.1177/1740774508100974 [PMC free article: PMC4651181] [PubMed: 19254935]

Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005;193(5):1630-9. PMID: 16260202. http://dx.doi.org/10​.1016/j.ajog.2005.05.005 [PubMed: 16260202]

Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled clinical trials. 2000;21(6 Suppl):273s-309s. PMID: 11189684. [PubMed: 11189684]

Menon U, Ryan A, Kalsi J, et al. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. 2015;33(18):2062-71. PMID: 25964255. http://dx.doi.org/10​.1200/JCO.2014.59.4945 [PMC free article: PMC4463475] [PubMed: 25964255]

Barrett J, Jenkins V, Farewell V, et al. Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). BJOG. 2014;121(9):1071-9. PMID: 24865441. http://dx.doi.org/10​.1111/1471-0528.12870 [PubMed: 24865441]

Spielberger C, Gorsuch R, Lushene R, et al. Manual for the Stait-Trait Anxiety Inventory (Form Y1–Y2). Palo Alto, CA: Consulting Psychology Press; 1983. PMID: None.

Goldberg D Manual of the General Health Questionnaire. Windsor: NFER-Nelso: 1978. PMID: None.

Gewandter JS, Smith SM, McKeown A, et al. Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations. Pain. 2014;155(3):461-6. PMID: 24275257. http://dx.doi.org/10​.1016/j.pain.2013.11.009 [PubMed: 24275257]

Moher D, Hopewell S, Schulz K, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340(c869). PMID: 20332511. http://dx.doi.org/10​.1136/bmj.c869 [PMC free article: PMC2844943] [PubMed: 20332511]

Fleming TR Clinical trials: discerning hype from substance. Ann Intern Med. 2010;153(6):400-6. PMID: 20855804. http://dx.doi.org/10​.7326/0003-4819-153-6-201009210-00008 [PMC free article: PMC3735615] [PubMed: 20855804]

Thornton JG, Bewley S Ovarian cancer screening: UKCTOCS trial. Lancet. 2016;387(10038):2601-2. PMID: 27353818. http://dx.doi.org/10​.1016/S0140-6736(16)30846-7 [PubMed: 27353818]

Menon U UK Collaborative Trial of Ovarian Cancer Screening. ISRCTN. 2017;ISRCTN22488978. PMID: None. http://dx.doi.org/10​.1186/ISRCTN22488978

Pinsky PF, Yu K, Kramer BS, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol. 2016. PMID: 27615399. http://dx.doi.org/10​.1016/j.ygyno.2016.08.334 [PMC free article: PMC5077651] [PubMed: 27615399]

Pinsky PF, Zhu C, Skates SJ, et al. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Int J Cancer. 2013;132(9):2127-33. PMID: 23065684. http://dx.doi.org/10​.1002/ijc.27909 [PubMed: 23065684]

Lai T, Kessel B, Ahn HJ, et al. Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer. J Gynecol Oncol. 2016;27(4):e41. PMID: 27102249. http://dx.doi.org/https://dx.doi.org/10​.3802/jgo.2016.27.e41 [PMC free article: PMC4864517] [PubMed: 27102249]

Henderson JT, Harper CC, Gutin S, et al. Routine bimanual pelvic examinations: practices and beliefs of US obstetrician-gynecologists. Am J Obstet Gynecol. 2013;208(2):109 e1-7. PMID: 23159688. http://dx.doi.org/10​.1016/j.ajog.2012.11.015 [PMC free article: PMC4350675] [PubMed: 23159688]

Guirguis-Blake J, Henderson J, Perdue L, et al. Screening for Gynecologic Conditions With Pelvic Examination: A Systematic Review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality; 2016. PMID: None. [PubMed: 28727393]

Temkin SM, Miller EA, Samimi G, et al. Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival. Eur J Cancer. 2017;87:182-8. PMID: 29156299. http://dx.doi.org/10​.1016/j.ejca.2017.10.015 [PubMed: 29156299]

Wennberg JE Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ. 2002;325(7370):961-4. PMID: 12399352. http://dx.doi.org/10​.1136/bmj.325.7370.961 [PMC free article: PMC1124450] [PubMed: 12399352]

Evans EC, Matteson KA, Orejuela FJ, et al. Salpingo-oophorectomy at the Time of Benign Hysterectomy: A Systematic Review. Obstet Gynecol. 2016;128(3):476-85. PMID: 27500347. http://dx.doi.org/10​.1097/AOG.0000000000001592 [PMC free article: PMC5100819] [PubMed: 27500347]

U. S. Preventive Services Task Force. U.S. Preventive Services Task Force Procedure Manual. Rockville, MD: U.S. Preventive Services Task Force; 2015. PMID: None.

Kobayashi H, Yamada Y, Sado T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer. 2008;18(3):414-20. PMID: 17645503. http://dx.doi.org/10​.1111/j.1525-1438.2007.01035.x [PubMed: 17645503]

van Nagell JR, Jr., Miller RW, DeSimone CP, et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol. 2011;118(6):1212-21. PMID: 22105249. http://dx.doi.org/10​.1097/AOG.0b013e318238d030 [PubMed: 22105249]

Miller RW, Pavlik EJ, Baldwin LA, et al. Complications from surgeries prompted by ovarian cancer screening. Gynecol Oncol. 2015;137:180. PMID: None. http://dx.doi.org/10​.1016/j.ygyno.2015.01.452

Lowder JL, Oliphant SS, Ghetti C, et al. Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979-2004. Am J Obstet Gynecol. 2010;202(6):538 e1-9. PMID: 20060093. http://dx.doi.org/10​.1016/j.ajog.2009.11.030 [PubMed: 20060093]

Rice MS, Hankinson SE, Tworoger SS Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' Health Studies. Fertil Steril. 2014;102(1):192-8 e3. PMID: 24825424. http://dx.doi.org/10​.1016/j.fertnstert.2014.03.041 [PMC free article: PMC4074555] [PubMed: 24825424]

Hanley GE, McAlpine JN, Pearce CL, et al. The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. Am J Obstet Gynecol. 2016. PMID: 27810554. http://dx.doi.org/10​.1016/j.ajog.2016.10.035 [PubMed: 27810554]

Garcia C, Martin M, Tucker LY, et al. Experience With Opportunistic Salpingectomy in a Large, Community-Based Health System in the United States. Obstet Gynecol. 2016;128(2):277-83. PMID: 27399999. http://dx.doi.org/10​.1097/AOG.0000000000001531 [PubMed: 27399999]

Russell MR, D'Amato A, Graham C, et al. Novel risk models for early detection and screening of ovarian cancer. Oncotarget. 2016. PMID: 27903971. http://dx.doi.org/10​.18632/oncotarget.13648 [PMC free article: PMC5352196] [PubMed: 27903971]

Drescher CW, Hawley S, Thorpe JD, et al. Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. Cancer Prev Res (Phila). 2012;5(8):1015-24. PMID: 22750949. http://dx.doi.org/10​.1158/1940-6207.CAPR-11-0468 [PMC free article: PMC3729263] [PubMed: 22750949]